Accounts Receivable turnover ratio remained unchanged during the second quarter 2026, compared to the previous quarter at 1.79 indicating more challenging environment then in the first quarter 2026, but still, it is a far cry from any concerns. Average collection period, for Ocular Therapeutix Inc 's accounts receivable remained unchanged at 204 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 489 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 3272 to 3283.

What is Receivable Turnover Ratio?
What is Ocular Therapeutix Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OCUL Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-0.5 %	-3.47 %	-5.37 %	1.76 %	0.6 %
Y / Y Revenue Change	0.12 %	0.81 %	-22.44 %	-5.71 %	-18.14 %
Receivable Turnover Ratio (TTM)	1.79	1.79	1.78	1.88	1.92
OCUL's Total Ranking	# 3283	# 3272	# 2835	# 1927	# 1787
Accounts Receivable average collection period days	203	204	206	194	190
Seq. Receivable Change	24.29 %	-20.56 %	-0.38 %	1.17 %	20.58 %
Seq. Revenue Change	24.94 %	-18.6 %	-8.9 %	8.06 %	25.81 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 167
Healthcare Sector	# 490
Overall Market	# 3283

Receivable Turnover Ratio Statistics
High	Average	Low
0.41	0.12	0.02
(Sep 30 2023)		(Dec 31 2014)

OCUL Company Profile • Back to OCUL Efficiency Comparisons • Compare OCUL Receivables Turnover Ratio to its Competitors

Financial Statements
Ocular Therapeutix Inc 's Accounts Receivable	$ 30 Millions	Visit OCUL's Balance sheet
Ocular Therapeutix Inc 's Sales TTM	$ 52 Millions	Visit OCUL's Income Statement
Sources of OCUL's Revenues		Visit OCUL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
OCUL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
OCUL's Growth Rates	OCUL's Roa	OCUL's Inventory Turnover Ratio	OCUL's Dividend Comparisons
OCUL's Profitability Ratios	OCUL's Roi	OCUL's Asset Turnover Ratio	OCUL's Dividend Growth
OCUL's Valuation Ratios	OCUL's Roe	OCUL's Financial Strength Ratios	OCUL's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Globus Medical Inc	4.70	$ 3,144.934 Millions	$ 669.166 Millions
Staar Surgical Co	4.69	$ 339.590 Millions	$ 72.454 Millions
Bausch and Lomb Corp	4.65	$ 5,324.000 Millions	$ 1,144.000 Millions
Kewaunee Scientific Corporation	4.63	$ 275.985 Millions	$ 59.584 Millions
Orasure Technologies Inc	4.62	$ 111.978 Millions	$ 24.227 Millions
Bristol myers Squibb Company	4.60	$ 49,186.000 Millions	$ 10,689.250 Millions
Omniab Inc	4.60	$ 38.457 Millions	$ 8.363 Millions
Yunhong Green Cti Ltd	4.58	$ 20.662 Millions	$ 4.513 Millions
Orthopediatrics Corp	4.56	$ 251.278 Millions	$ 55.123 Millions
Cryo cell International Inc	4.54	$ 31.128 Millions	$ 6.851 Millions
Aligos Therapeutics Inc	4.54	$ 31.518 Millions	$ 6.945 Millions
Bioventus Inc	4.49	$ 581.106 Millions	$ 129.410 Millions
Fulgent Genetics Inc	4.45	$ 322.973 Millions	$ 72.541 Millions
Gyre Therapeutics Inc	4.43	$ 119.383 Millions	$ 26.928 Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________	4.42	$ 25.185 Millions	$ 5.695 Millions
Supernus Pharmaceuticals inc	4.41	$ 830.438 Millions	$ 188.224 Millions
Eli Lilly And Company	4.40	$ 79,665.800 Millions	$ 18,094.850 Millions
Neurocrine Biosciences Inc	4.40	$ 3,373.900 Millions	$ 767.475 Millions
Lantheus Holdings Inc	4.39	$ 1,555.343 Millions	$ 354.642 Millions
Waters Corporation	4.38	$ 4,644.249 Millions	$ 1,059.341 Millions
Organon and Co	4.31	$ 6,139.000 Millions	$ 1,422.750 Millions
Vsee Health Inc	4.30	$ 10.759 Millions	$ 2.500 Millions
Alkermes Plc	4.30	$ 1,667.652 Millions	$ 388.132 Millions
Glaukos Corp	4.29	$ 500.031 Millions	$ 116.471 Millions
Dexcom Inc	4.25	$ 4,968.800 Millions	$ 1,168.000 Millions
Vericel Corporation	4.18	$ 306.303 Millions	$ 73.289 Millions
Retractable Technologies Inc	4.14	$ 33.488 Millions	$ 8.087 Millions
Apyx Medical Corp	4.14	$ 58.105 Millions	$ 14.035 Millions
Regenxbio Inc	4.13	$ 174.482 Millions	$ 42.238 Millions
Revvity Inc	4.12	$ 2,911.811 Millions	$ 706.371 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.